Blue Earth Diagnostics was founded in March 2014 to develop and commercialise molecular imaging agents, addressing areas of high unmet medical need

The company’s first approved and commercially available product, Axumin®, is clinically proven to target and image prostate cancer cells. Axumin was reviewed by the US Food and Drug Administration and was granted US regulatory approval in Q2 2016. Marketing authorisation in Europe was granted by the European Medicines Agency in Q2 2017.

Blue Earth Diagnostics is investigating the utility of Axumin, the imaging of other cancers, such as glioma. In May 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (‘PSMA’)-targeted radiohybrid (‘rh’) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.


Jonathan Allis

Chief Executive Officer

“Syncona partners have enabled us to take an undervalued asset out of a major healthcare company, and turn it into an exceptional business opportunity. I have found Syncona Partners to be genuinely interested in our business, rather than just the financials. They have provided major commercial and marketing insights, and helped us to build a better business.”